When I first started OncTalk, there was a lot of buzz about celebrex (celecoxib) as a cancer drug, but almost all of it was among patients talking about it on the internet: oncologists watching the field hadn't been impressed by the early returns, including this one (despite the fact that some of my earliest work in lung cancer was on cyclo-oxygenase-2, or COX-2, the target of celebrex).

Celecoxib (Celebrex) has been studied in combination with chemo for NSCLC and has generated enough promising results to raise expectations but also enough negative data to produce disappointment. Dr.

We'll break from brain metastases for a while to talk about another potential avenue of targeted therapy in lung cancer: the cyclo-oxygenase, or COX, pathway.